ClinicalTrials.gg
CompletedNCT06100627Updated May 10, 2024

A Pharmacodynamic Effect Study of AP301 in Healthy Volunteers

A Phase 1 interventional study of AP301 in Healthy Subjects, sponsored by Alebund Pty Ltd. Completed at 1 site in Australia. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-05-10.

Sponsored by Alebund Pty Ltd · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
Male
01

Study summary

This is a randomized, open-label, parallel-group, phase 1 study to evaluate the PD effect of AP301 capsule in healthy volunteers. The study is planned to have 4 treatment arms: Arm 1: 2.10 g/day; arm 2: 4.20 g/day; arm 3: 6.30 g/day; arm 4: 8.40 g/day.

Read the detailed description

A total of 32 participants will participate in this study and the study consists of 3 periods such as screening period, hospitalization period and follow up period.

02

Conditions studied

  • Healthy Subjects

Keywords

  • Pharmacodynamic
  • safety
  • tolerability
  • AP301
  • Healthy subjects
03

In context

Lead sponsor

Alebund Pty Ltd is the lead sponsor of 2 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Eligibility criteria

Important Inclusion Criteria:

  • Healthy male volunteers, 18-55 years of age
  • (BMI) 18-30 kg/m2 (exclusive) at screening.

Important Exclusion Criteria:

  • Serum phosphorus is below 1.00 mmol/L at screening.
  • History of significant gastrointestinal disease or disorder, major gastrointestinal surgeries, or cholecystectomy
  • History or symptoms of any kidney, liver, broncho-pulmonary, gastrointestinal, neurological, psychiatric, cardiovascular, endocrine/metabolic, hematological diseases, or cancer.
  • History of specific allergies or allergic conditions or known allergies to the study drug as judged by the investigator, or any confirmed significant allergic reactions (urticaria or anaphylaxis) to any drug, or multiple drug allergies (non-active hay fever is acceptable). Allowing for childhood asthma, history of mild eczema that has had no flare ups for ≥5 years or is fully resolved.
  • Known history of allergy to common food like milk or gluten, or lactose intolerance, or special diet habit for religious/life-style reasons, which might potentially jeopardize the participant's compliance of study diet.
  • Any clinically significant concomitant disease, or condition or treatment that could interfere with the conduct of the study.
  • Confirmed (based on the average of 3 separate resting blood pressure measurements, after at least 5 minutes rest) systolic blood pressure (BP) greater than 150 or less than 90 mmHg, and diastolic BP greater than 90 or less than 50 mmHg at screening.
  • Clinically relevant abnormalities on screening ECG.
  • Estimated (eGFR) ≤ 70 mL/min/1.73 m2.
  • Positive test at screening of any of the following: (HBsAg), (HCV Ab) or (HIV-1 or HIV-2 Ab).
  • (ALT) or aspartate transaminase (AST) > 1.5 × (ULN), or any other clinically significant abnormalities in laboratory test results at screening.
  • Dosed with a small-molecule or biologic drug within 30 days or 90 days, respectively, or 5 half-lives (whichever is the longer) prior to first dose of this study.
  • Positive urine test for drugs of abuse and/or positive alcohol test at screening.
  • Any medical or social conditions that, in the view of investigator, might potentially jeopardize the participant's compliance of study.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    2.10 g/day of AP301

    Drug: AP301

  • Experimental
    4.20 g/day of AP301

    Drug: AP301

  • Experimental
    6.30 g/day of AP301

    Drug: AP301

  • Experimental
    8.40 g.day of AP301

    Drug: AP301

Interventions

  • DrugAP301

    Orally administered

06

What researchers measure

Primary outcomes

  1. Urinary phosphorus excretion during AP301 administration

    Average daily urinary phosphorus excretion during the 3 consecutive days of AP301 treatment

    Time frame: From the Day 1 to Day 4 after dosing, assessed up to 3 days

  2. Effect of AP301 on urinary phosphorus excretion

    Change of average daily urinary phosphorus excretion from 3 days before treatment to 3 days during treatment.

    Time frame: From Day -3 to Day 4 after dosing, assessed up to 6 days

  3. Urinary calcium excretion during AP301 administration

    Average daily urinary calcium excretion during the 3 consecutive days of AP301 treatment.

    Time frame: From the Day 1 to Day 4 after dosing, assessed up to 3 days

  4. Effect of AP301 on urinary calcium excretion

    Change of average daily urinary calcium excretion from 3 days before treatment to 3 days during treatment.

    Time frame: From Day -3 to Day 4 after dosing, assessed up to 6 days

  5. Effect of AP301 on serum phosphorus and calcium

    Changes of serum phosphorus and serum calcium from baseline to end of treatment.

    Time frame: From Day -3 to Day 4 after dosing, assessed up to 6 days

Secondary outcomes

  1. Incidence and severity of adverse events (AEs)

    Number of participants with adverse events (AEs) and the intensity of adverse events. Number of participants with serious adverse events (SAEs) and the intensity of adverse events.

    Time frame: From screening to hospitalization and follow up periods, assessed up to 43 days

  2. Changes in clinical laboratory values

    Changes and their clinical meaningfulness in clinical laboratory values: Hematology, Biochemistry, Urinalysis

    Time frame: From screening to hospitalization and follow up periods, assessed up to 43 days

  3. Abnormal electrocardiogram (ECG) readings and their clinical meaningfulness

    ECG intervals (PR \[PQ\], QRS, QT, QTcF) and heart rate

    Time frame: From screening to hospitalization and follow up periods, assessed up to 43 days

  4. Changes of ECG parameters and their clinical meaningfulness

    ECG intervals (PR \[PQ\], QRS, QT, QTcF), heart rate, T-wave morphology and U-wave morphology.

    Time frame: From screening to hospitalization and follow up periods, assessed up to 43 days

  5. Abnormal vital signs and their clinical meaningfulness

    Blood pressure, heart rate and body temperature

    Time frame: From screening to hospitalization and follow up periods, assessed up to 43 days

07

Study locations

1 site
  • Nucleus Network Pty Ltd
    Melbourne, Victoria 3004, Australia
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2024 to primary completion in Feb 2024, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 17, 2023
First posted
Oct 25, 2023
StartActual
Jan 11, 2024
Primary completionActual
Feb 8, 2024
CompletionActual
Feb 28, 2024
Last update
May 10, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 10, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06100627
Lead sponsor
Alebund Pty Ltd
Responsible party
Sponsor
First posted
Oct 25, 2023
Start date
Jan 11, 2024
Primary completion
Feb 8, 2024
Completion
Feb 28, 2024
Last update
May 10, 2024

Study contacts

Sam Francis, Doctor
principal investigator · Nucleus Network

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: AP301 peptide

Start the discussion